Jupiter Topco LLC bought a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 9,783,192 shares of the company’s stock, valued at approximately $100,816,000. Jupiter Topco LLC owned 0.14% of Immix Biopharma at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Immix Biopharma by 4.5% during the third quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock worth $1,526,000 after purchasing an additional 31,625 shares in the last quarter. Tocqueville Asset Management L.P. grew its position in shares of Immix Biopharma by 37.4% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock valued at $84,000 after buying an additional 10,950 shares during the last quarter. Imprint Wealth LLC acquired a new stake in Immix Biopharma during the 3rd quarter worth $141,000. Citadel Advisors LLC purchased a new stake in Immix Biopharma in the third quarter valued at $188,000. Finally, Susquehanna International Group LLP boosted its stake in Immix Biopharma by 78.8% in the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock valued at $190,000 after acquiring an additional 40,032 shares in the last quarter. 11.26% of the stock is owned by institutional investors and hedge funds.
Immix Biopharma Stock Performance
NASDAQ IMMX opened at $14.07 on Thursday. The firm’s fifty day moving average is $10.40 and its two-hundred day moving average is $9.46. Immix Biopharma, Inc. has a one year low of $1.94 and a one year high of $15.10. The firm has a market cap of $1.01 billion, a PE ratio of -15.99 and a beta of 0.11.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a report on Friday, July 17th. Bank of America started coverage on Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 price target on the stock. Lifesci Capital initiated coverage on Immix Biopharma in a research report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price target on the stock. HC Wainwright boosted their price objective on Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Finally, Morgan Stanley decreased their price objective on Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.29.
Get Our Latest Stock Report on Immix Biopharma
About Immix Biopharma
Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Featured Stories
- Five stocks we like better than Immix Biopharma
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding IMMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report).
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
